Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

Tubridy, Karen

Karen Tubridy is the Chief Development Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics.  Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio.  She has had responsibility for driving global program strategies to IND,

 READ MORE

Karen Tubridy

Chief Development Officer

x

Karen Tubridy

Chief Development Officer

Karen Tubridy is the Chief Development Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics.  Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio.  She has had responsibility for driving global program strategies to IND, NDA and J-NDA filings.  In addition, she has had responsibility for oversight of drug development operations including the build out of core R&D infrastructure and quality systems. Previously, she held senior positions in clinical and regulatory operations at Inspiration Biopharmaceuticals, Taligen Therapeutics (acquired by Alexion) and Syntonix Pharmaceuticals (acquired by Biogen).  She held a senior position at AVANT Immunotherapeutics directing several vaccine programs and held positions of increasing responsibility in clinical research and medical affairs at Genetics Institute/Wyeth Pharmaceuticals, where she directed hematology and oncology programs.  Karen holds a B.S. in pharmacy and a PharmD from the Massachusetts College of Pharmacy and Allied Health Sciences.

Martin, Alex

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA

 READ MORE

Alex Martin

Chief Executive Officer

x

Alex Martin

Chief Executive Officer

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX). He was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). He began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Alex is an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. He holds a BA from Cornell University and an MBA from Harvard

Gress, Mike

Mike Gress

VP, Clinical Development,
Head of Clinical Trial Management

x

Mike Gress

VP, Clinical Development,
Head of Clinical Trial Management

Cooper, Ken

Ken Cooper

Clinical Operations, Trial Management

x

Ken Cooper

Clinical Operations, Trial Management

Weems Gary

Garry Weems

VP, Clinical Science

x

Garry Weems

VP, Clinical Science

Wilkins, Jeffrey

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among

 READ MORE

H. Jeffrey Wilkins, MD

Chief Medical Officer

x

H. Jeffrey Wilkins, MD

Chief Medical Officer

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his M.D. from Temple University School of Medicine and his B.S. from Bucknell University.

Subramanyam, Janaki

Janaki (Jana) Subramanyam is Vice President, Head of Regulatory Affairs at Abcuro. Jana is an experienced regulatory affairs professional having worked on small molecule and biologic development programs across rheumatology, nephrology, neurology, and psychiatry for more than twenty years. Her regulatory drug development expertise spans clinical, nonclinical, manufacturing, quality, post marketing advertising, and promotional activities.

 READ MORE

Janaki M. Subramanyam

VP, Head of Regulatory Affairs

x

Janaki M. Subramanyam

VP, Head of Regulatory Affairs

Janaki (Jana) Subramanyam is Vice President, Head of Regulatory Affairs at Abcuro. Jana is an experienced regulatory affairs professional having worked on small molecule and biologic development programs across rheumatology, nephrology, neurology, and psychiatry for more than twenty years. Her regulatory drug development expertise spans clinical, nonclinical, manufacturing, quality, post marketing advertising, and promotional activities. Prior to joining Abcuro, Jana was the Head of Regulatory Affairs at Allena Pharmaceuticals, Inc. where she helped develop two assets for rare metabolic diseases. Jana also held leadership roles in regulatory affairs at FORUM Pharmaceuticals, Lantheus Medical Imaging, and AMAG Pharmaceuticals. She received her M.S. in microbiology from Ohio University and her B.S. in microbiology and biochemistry from Bombay Universit

Searle, Stephen

Stephen A. Searle

Senior Program Manager

x

Stephen A. Searle

Senior Program Manager

Hwang, Ella

Ella Hwang

Senior Director, Quality

x

Ella Hwang

Senior Director, Quality

Shen, Yuyi

Yuyi Shen, PhD

VP, Technical Operations

x

Yuyi Shen, PhD

VP, Technical Operations

Reyes, Armando

Armando Reyes

Associate Clinical Director

x

Armando Reyes

Associate Clinical Director

Ward, Antonio

Antonio Ward, PhD

Senior Scientist

x

Antonio Ward, PhD

Senior Scientist

Rozzo, Aldo

Aldo Rozzo, PhD, DVM

Lab Manager

x

Aldo Rozzo, PhD, DVM

Lab Manager

Motschwiller, Ricky

Richard Motschwiller

Controller

x

Richard Motschwiller

Controller

McClain, Michael

Michael McClain

Clinical Trial Manager

x

Michael McClain

Clinical Trial Manager

LeMessurier, Hugo

Hugo LeMessurier

Director, Abcuro Pty Ltd

x

Hugo LeMessurier

Director, Abcuro Pty Ltd

Jiang, Lusi

Lusi Jiang

Senior Accountant

x

Lusi Jiang

Senior Accountant

Hoffer, LaDonna

LaDonna Hoffer

Senior Director, Operations

x

LaDonna Hoffer

Senior Director, Operations

Chartienitz, Brett

Brett Chartienitz

IT Operations Manager

x

Brett Chartienitz

IT Operations Manager

Borbas, Dave

Dave Borbas

Research VP,
Head of Data Management

x

Dave Borbas

Research VP,
Head of Data Management

Anderson, Jeff

Jeff Anderson

Office Manager

x

Jeff Anderson

Office Manager

Greenberg, Steven A.

Steven A Greenberg, M.D., M.S. is a founder of Abcuro and is the Chair of the Medical Advisory Board. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion

 READ MORE

Steven A. Greenberg, MD

Chief Scientific Advisor and
Chair, Medical Advisory Board

x

Steven A. Greenberg, MD

Chief Scientific Advisor and
Chair, Medical Advisory Board

Steven A Greenberg, M.D., M.S. is a founder of Abcuro and is the Chair of the Medical Advisory Board. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion body myositis, and therapeutics, including co-inventing a therapeutic monoclonal antibody for dermatomyositis currently in late-stage clinical trials. He has authored over 100 publications and served as Principal Investigator for multiple clinical trials. Steve received an A.B. degree in Mathematics from Princeton University, an M.S. degree in Medical Informatics from Massachusetts Institute of Technology, and an M.D. degree from Harvard Medical School through the Harvard-MIT Health Science and Technology Program.

Edwards, John

John Edwards brings over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals. He was involved in the development or commercialization of ten FDA-approved biologics and has had successful exits at eight of the ten biotech companies he helped to build, including Tilos Therapeutics, Siamab Therapeutics, Exonics Therapeutics, Adnexus Therapeutics, F-star Therapeutics,

 READ MORE

John Edwards

Executive Chair

x

John Edwards

Executive Chair

John Edwards brings over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals. He was involved in the development or commercialization of ten FDA-approved biologics and has had successful exits at eight of the ten biotech companies he helped to build, including Tilos Therapeutics, Siamab Therapeutics, Exonics Therapeutics, Adnexus Therapeutics, F-star Therapeutics, and Genetics Institute. He built a hematology therapeutic business that reached over $1 billion in annual revenue for Wyeth/Genetics Institute and was responsible for leading the development of the fastest biologic to progress from phase I to FDA approval. John started his career in research and development as one of the first employees at Genzyme. He received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the University of Massachusetts at Amherst.

Deware, Patricia

Patricia Deware

VP, Finance and Planning

x

Patricia Deware

VP, Finance and Planning

Privacy Site Credits Terms of Use

© 2023 Abcuro